

# Subject Index

- ABCD score, in TIA, 47–50  
ABCD-DM<sup>2</sup> score, in TIA, 47–50  
Abdominal obesity  
  cerebral infarction and, 54–55  
  stroke and, 28–29  
ACAS (Asymptomatic Carotid Atherosclerosis Study), 122  
ACCESS study, 10  
ACCOMPLISH (Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension), 18  
ACCORD (Action to Control Cardiovascular Risk in Diabetes), 20  
Acetazolamide reactivity, 72  
Action research arm test, for rehabilitation, 147  
Action to Control Cardiovascular Risk in Diabetes (ACCORD), 20  
Activated partial thromboplastin time, for anticoagulant therapy, in cerebral venous/venous sinus occlusion, 138–139  
ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events), 23  
ACTIVE W study, 23  
Activities of daily living, rehabilitation for, 156–158  
  with cognitive impairment, 173–175  
  in convalescent phase, 153–154  
  with decreased physical fitness, 175–177  
  with osteoporosis, 177–178  
  in prognosis prediction, 149–150  
  with upper limb impairment, 161–163  
Acute cerebral infarction, 32–45  
Acute phase, of rehabilitation, 146, 150–153  
Aerobic exercise, for decreased physical fitness, 175–177  
Agnosia, rehabilitation for, 17–17  
AHA (American Heart Association), antihypertensive therapy guidelines of, 10  
Airway management  
  for intracerebral hemorrhage, 80  
  for stroke, 9  
Albumin, for cerebral infarction, 38–40  
Alcohol consumption  
  cerebral infarction and, 53–54  
  intracerebral hemorrhage and, 75–77  
  subarachnoid hemorrhage risk in  
  in transient ischemic attack, 46–50  
Alexia, rehabilitation for, 173–175  
ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial), 16–17, 20  
Alpha blockers, for urinary disturbances, 170–171  
Alteplase. *See* Recombinant tissue plasminogen activator (rt-PA, alteplase)  
Alzheimer's disease, 142–143  
Ambulation, early, 151  
American Heart Association, antihypertensive therapy guidelines of, 10  
Amitriptyline, for central pain, 167–168  
Amlodipine, for stroke prevention, 16–18  
Amphetamine, for motor impairment rehabilitation, 157  
Amyloid angiopathy, cerebral, 139–140  
Ancrod, for cerebral infarction, 40  
Aneurysm(s), cerebral  
  arteriovenous malformations with, 89  
  dissecting, 103, 130–133  
  identification of, 101–102  
  ruptured  
    risk for, 126  
    treatment of, 107–110  
    treatment of  
      conservative, 113–115  
      endovascular, 110–113  
      follow-up in, 112  
      initial, 102–105  
      multimodal, 109  
      perioperative management in, 109–110  
      procedures for, 108–109  
      ruptured, 107–110  
      selection of methods for, 106–107  
      timing of, 107–108  
      unruptured, 125–128  
  unruptured  
    diagnosis of, 124–125  
    early actions for, 125  
    natural history of, 125–126  
    treatment of, 125–128  
Angiomas  
  cavernous, 94–95  
  venous, 95–96  
Angioplasty, for cerebral infarction, 44, 72  
Angiotensin-converting enzyme inhibitors  
  for cerebral infarction prevention, 50–51, 68–69  
  for intracerebral hemorrhage, 78  
  for stroke prevention, 16–19  
  for stroke treatment, 10  
  for transient ischemic attack, 46–50  
Angiotensin-receptor blockers  
  for cerebral infarction prevention, 51  
  for intracerebral hemorrhage, 78  
  for stroke prevention, 17, 18  
Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA), 17  
Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA), 21  
Ankle-foot orthosis, for gait training, 159–161  
Anterior tibial muscle transfer, for gait training, 159  
Anticardiolipin antibodies, cerebral infarction and, 56–57  
Anticholinergics, for urinary disturbances, 170–171  
Anticoagulants  
  for arterial dissection, 130–132  
  for asymptomatic intracerebral hemorrhage, 120–121  
  for cerebral aneurysms, 112–113  
  for cerebral arterial dissection, 45  
  for cerebral infarction prevention, 63–67  
  for cerebral infarction treatment, 36–37  
  for cerebral venous/venous sinus occlusion, 46, 138–139  
  intracerebral hemorrhage due to, 96–98  
  for moyamoya disease, 134  
  for thrombosis, in patent foramen ovale, 136–138  
AntiCoagulation and Risk factors in ATrial fibrillation (ATRIA) study, 65  
Anticonvulsants  
  for intracerebral hemorrhage, 83–84  
  for moyamoya disease, 134  
Antidepressants  
  after cerebral infarction, 68

- for depressive state, 179–180
- for intracerebral hemorrhage, 83–84
- Antiepileptics
  - for intracerebral hemorrhage, 81, 83
  - for moyamoya disease, 134
- Antifibrinolytic agents, for subarachnoid hemorrhage, 103
- Antihypertensive(s)
  - for asymptomatic cerebral infarction, 117–118
  - for asymptomatic intracerebral hemorrhage, 120–121
  - for cerebral infarction prevention, 50–51
  - for chronic kidney disease, 29–30
  - for hypertensive encephalopathy, 141
  - for intracerebral hemorrhage prevention, 75–77
  - for intracerebral hemorrhage treatment, 78–79
  - for moyamoya disease, 134–135
  - for stroke prevention, 16–19
  - for stroke treatment, 9–10
  - for subarachnoid hemorrhage, 103
  - for transient ischemic attack, 46–50
- Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 16–17, 20
- Antihypertensive Treatment in Acute Cerebral Hemorrhage (ATACH) trial, 78–79
- Antioxidants, for cerebral infarction, 38–39
- Antiphospholipid syndrome, cerebral infarction and, 56–57
- Antiplasmin agents, 61, 77–78
- Antiplatelet therapy. *See also specific agents*
  - for aortitis syndrome, 141
  - for arterial dissection, 130–132
  - for asymptomatic intracerebral hemorrhage, 120–121
  - for carotid stenosis/occlusion, 122–123
  - for cerebral arterial dissection, 45
  - for cerebral artery stenosis, 121–122
  - for cerebral infarction
    - acute, 37–38
    - asymptomatic, 117–118
    - chronic, 58–63
  - intracerebral hemorrhage and, 76–77, 96–98
  - for moyamoya disease, 134–135
  - for transient ischemic attack, 46–50
- Antipyretics
  - for cerebral infarction, 41
  - for stroke, 12–13
- Antithrombin-III, in thrombophilia, 58
- Antithrombotic therapy, for arterial dissection, 130–132
- Antithrombotic Trialists Collaboration (ATT), 59
- Anxiety, with cerebral aneurysms, 125
- Aorta, dissection of, cerebral infarction with, 45–46
- Aortitis syndrome, 140–141
- Aphasia, rehabilitation for, 171–175
- Apnea-hypopnea index, stroke and, 27
- Apolipoprotein E, in cerebral aneurysms, 126
- Apraxia, rehabilitation for, 173–175
- ARBs. *See* Angiotensin-receptor blockers
- Argatroban, for cerebral infarction, 36–37
- Arms, impairment of, rehabilitation for, 161–163
- Arrhythmias, in subarachnoid hemorrhage, 103
- Arterial dissection
  - headache in, 14
  - medical treatment of, 130–131
  - surgical treatment of, 131–133
- Arteriovenous fistulas, dural, intracerebral hemorrhage in, 92–93
- Arteriovenous malformations
  - aneurysms with, 89
  - asymptomatic, 123–124
  - intracerebral hemorrhage in, 88–92
  - natural history of, 89
  - in pediatric patients, 90
  - risk factors for bleeding in, 89
  - surgical treatment of, 89–90
- Artery-to-artery embolism, 61
- Arthritis, in rehabilitation, 151
- Artificial respiratory management, 9, 80
- Arundic acid, for cerebral infarction, 38–39
- ASCOT-BOLA (Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm), 17
- ASCOT-LLA (Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm), 21
- Ashworth Scale and Modified Ashworth Scale, for rehabilitation, 147–148
- Asian Pacific Cohort Studies Collaboration trial, 21
- Aspiration, during swallowing, 168–170
- Aspiration pneumonia
  - in dysphagia, 13–14
  - prevention of, 68–69
- Aspirin
  - for atrial fibrillation, 23–25
  - for cerebral infarction
    - acute, 37–38
    - with antiphospholipid syndrome, 56–57
    - asymptomatic, 117
    - with atrial fibrillation, 55
    - with hypertension, 51
    - preventive, 58–61, 63–67
  - for thrombosis prevention, 41–43
  - intracerebral hemorrhage due to, 96–98
  - for moyamoya disease, 134–135
  - for thrombosis, in patent foramen ovale, 136–138
  - for transient ischemic attack, 46–50
  - for vascular dementia and cognitive impairment, 142–143
- ASPREE trial, 143
- Assessment methods, for rehabilitation, 147–149
- Asymptomatic Carotid Atherosclerosis Study, 122
- Asymptomatic cerebrovascular diseases, 116–128
  - cavernous angiomas, 94–95
  - cerebral arteriovenous malformations, 123–124
  - cerebral infarction, 117–118
  - cervical/intracerebral vascular stenosis/occlusion, 121–123
  - dural arteriovenous fistula, 92–93
  - intracerebral hemorrhage, 120–121
  - moyamoya disease, 135
  - unruptured cerebral aneurysms, 124–128
  - venous angiomas, 95–96
  - white matter lesions, 118–120
- ATACH (Antihypertensive Treatment in Acute Cerebral Hemorrhage) trial, 78–79
- Atenolol, for stroke prevention, 17
- Atherosclerosis
  - of cerebral artery, 121–122
  - of cervical carotid artery, 122–123
- Atherothrombotic cerebral infarction
  - antiplatelet therapy for, 58–63
  - brain edema in, 39–40
  - incidence of, 31
- Atorvastatin
  - for cerebral infarction prevention, 52–53
  - for cerebral infarction treatment, 32, 48
  - for stroke prevention, 21
- ATRIA (AnTicoagulation and Risk factors in ATrial fibrillation) study, 65
- Atrial fibrillation
  - cerebral infarction in, 55
  - inhibition of, 17
  - nonvalvular, cerebral infarction in, 36–37

- stroke in, 23–25
  - transient ischemic attack and, 46–50
- ATT (Antithrombotic Trialists Collaboration), 59
- Attention disturbances, rehabilitation for, 173–175
- Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH), 18
- Baclofen, for spasticity, 163–166
- Balloon dilatation, for dysphagia, 168–170
- Bandage, for shoulder impairment, 166–167
- Barthel Index, for rehabilitation, 147–148
- Basal ganglia hemorrhage, 85
- BAT (Bleeding with Antithrombotic Therapy) study, 61, 65
- Batroxobin, for cerebral infarction, 40, 56
- Bed rest, complications of, 151
- Benazepril, for stroke prevention, 18
- Berg balance scale, for rehabilitation, 147
- Beta blockers
  - for intracerebral hemorrhage, 78
  - for stroke prevention, 16–19
  - for stroke treatment, 10
- Biofeedback
  - for gait training, 159
  - for urinary disturbances, 171
- Bladder training, for urinary disturbances, 170–171
- Bleeding. *See also* Hemorrhage
  - gastrointestinal
    - in intracerebral hemorrhage, 81
    - in stroke, 12
  - repeat. *See* Rebleeding
  - in small amounts. *See* Microbleeds
- Bleeding with Antithrombotic Therapy (BAT) study, 61, 65
- Blood pressure. *See also* Hypertension; Hypotension
  - alterations in, in rehabilitation, 151
  - control of
    - in cerebral aneurysm repair, 109
    - in intracerebral hemorrhage, 78–79
    - in stroke, 9–10
    - in thrombolytic therapy, 33
- Bobath method, 157
- Body mass index, cerebral infarction and, 54–55
- Bone atrophy, rehabilitation for, 177–178
- Borden classification, for dural arteriovenous fistulas, 92–93
- Botulinum toxin
  - for shoulder impairment, 166–167
  - for spasticity, 163–166
- Brain
  - edema of
    - in cerebral infarction, 39–40
    - in intracerebral hemorrhage, 80–81
    - in stroke, 11
  - tumors of, intracerebral hemorrhage with, 96
- Brain Check-Up screening program, 117
- Brainstem
  - cavernous angiomas of, 94–95
  - compression of, 43–44
  - hemorrhage of, 85–88
- Breath-holding swallowing, 168–170
- Bridging activity, for decreased physical fitness, 175–177
- Brunnstrom method, 157
- Brunnstrom stage, 147–148
- Budralazine, contraindicated for intracerebral hemorrhage, 79
- Bupleurum powder, for vascular dementia and cognitive impairment, 143
- Burr hole surgery, for moyamoya disease, 133–134
- Bypass procedures
  - for cerebral artery stenosis, 121–122
  - for cerebral infarction, 72–73
  - for moyamoya disease, 133–134
- Cadralazine, contraindicated, for intracerebral hemorrhage, 79
- Calcium antagonists
  - for cerebral infarction, 38–39
  - for intracerebral hemorrhage, 78
  - for stroke prevention, 16–19
  - for stroke treatment, 10
- Calcium supplements, for osteoporosis, 177–178
- Candesartan, for vascular dementia and cognitive impairment, 142
- Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J), 17
- Capillary stabilizers, for intracerebral hemorrhage, 77–78
- CAPRIE (Clopidogrel versus Aspirin in Patients at Risk for Ischaemic Events), trial, 59–60
- CARAT (Cerebral Aneurysm Rupture After Treatment) study, 106
- Carbamazepine, for central pain, 167–168
- Cardioembolic stroke
  - antiplatelet therapy for, 63
  - in atrial fibrillation, 36–37
  - brain edema in, 39–40
  - incidence of, 31
- Cardiomyopathy, Tako-Tsubo, in subarachnoid hemorrhage, 103
- Cardiopulmonary resuscitation, for subarachnoid hemorrhage, 103
- Cardiovascular Health Study, for asymptomatic cerebral infarction, 117
- CARDS (Collaborative Atorvastatin Diabetic Study), 19, 21
- CARE (Cholesterol Current Events) study, 20
- Carotid artery
  - cervical
    - revascularization of, for cerebral infarction, 44
    - stenosis/occlusion of, 122–123
  - internal, dissection of, 130–131
  - stenting of, for cerebral infarction prevention, 70–72
- Carotid endarterectomy
  - for carotid stenosis/occlusion, 122–123
  - for cerebral infarction prevention, 69–70
  - for cerebral infarction treatment, 44
  - for transient ischemic attack, 46–50
- CAS (carotid artery stenting), for cerebral infarction prevention, 70–72
- CASE-J (Candesartan Antihypertensive Survival Evaluation in Japan), 17
- CASISP (Cilostazol versus Aspirin for Secondary Ischaemic Stroke Prevention), 60
- Catheterization, for urinary disturbances, 17
- Caudate nucleus hemorrhage, 86
- Cavernous angioma, intracerebral hemorrhage in, 94–95
- Cavernous sinus, arteriovenous fistula in, 92–93
- Central pain, rehabilitation for, 167–168
- Cerebellum
  - cavernous angiomas of, 94–95
  - hemorrhage of, 84–88
  - infarction of, 43–44
- Cerebral Aneurysm Rupture After Treatment (CARAT) study, 106
- Cerebral aneurysms. *See* Aneurysm(s), cerebral
- Cerebral angiography
  - for dural arteriovenous fistula, 92–93
  - for subarachnoid hemorrhage, 103
  - for vasospasm, 114

- Cerebral arteriovenous malformations. *See* Arteriovenous malformations
- Cerebral artery  
 dissection of, 45  
 middle, rt-PA administration to, 35–36  
 stenosis of, 121–122
- Cerebral circulation and metabolism enhancers, 67–68
- Cerebral herniation, 9
- Cerebral infarction. *See* Infarction, cerebral
- Cerebral venous occlusion, 46, 138–139
- CHADS score, 23, 66
- CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) trial, 47–50, 61
- Chedoke-McMaster stroke assessment, for rehabilitation, 147
- Chlorthalidone, for stroke prevention, 16–17
- Cholesterol, control of, for cerebral infarction prevention, 52–53
- Cholesterol Current Events (CARE) study, 20
- Cholesterol Treatment Trialists (CIT), 19
- Cholinergic drugs, for urinary disturbances, 170–171
- Cholinesterase inhibitors, for vascular dementia, 142–143
- Chronic cerebral infarction, 50–73
- Chronic kidney disease, stroke and, 29–30
- Chronic phase, of rehabilitation, 146, 154–156
- Cilostazol  
 for cerebral infarction prevention, 58–63, 68–69  
 for transient ischemic attack, 46–50
- Cilostazol Stroke Prevention Study (CSPS), 60, 63
- Cilostazol versus Aspirin for Secondary Ischaemic Stroke Prevention (CASISP), 60
- Cimetidine, for intracerebral hemorrhage, 81
- Circle of Willis, moyamoya disease of. *See* Moyamoya disease
- CIT (Cholesterol Treatment Trialists), 19
- Citalopram, for depression, 68
- Citicoline, for cerebral infarction, 38–39
- Clipping, of cerebral aneurysms, 108–109
- Clopidogrel  
 for atrial fibrillation, 23  
 for cerebral infarction prevention, 58–61  
 for cerebral infarction treatment, 32, 37–38  
 intracerebral hemorrhage due to, 96–98  
 for moyamoya disease, 135  
 for transient ischemic attack, 46–50
- Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial, 47–50, 61
- Clopidogrel versus Aspirin in Patients at Risk for Ischaemic Events (CAPRIE) trial, 59–60
- Clotting factors, for intracerebral hemorrhage, 77–78
- Coating, of cerebral aneurysms, 108–109
- Cognitive behavioral therapy, for depressive state, 179–180
- Cognitive impairment  
 rehabilitation for, 173–175  
 vascular, 142–143
- Coil embolization, for cerebral aneurysms, 110–113, 127
- Cold therapy, for spasticity, 163–166
- Cold-water stimulation of left ear, for hemispatial neglect, 173–175
- Collaborative Atorvastatin Diabetic Study (CARDS), 19, 21
- Communication disorders, rehabilitation for, 171–172
- Community rehabilitation, in chronic phase, 154–156
- Compensatory exercises, for cognitive impairment, 173–175
- Complications, 12–13. *See also specific complications*
- Compression stockings  
 for cerebral infarction, 41–43  
 for intracerebral hemorrhage, 82
- Computed tomography  
 for cerebral infarction, 43–44  
 for unruptured cerebral aneurysms, 124–125
- Computed tomography angiography  
 for aortitis syndrome, 140–141  
 for subarachnoid hemorrhage, 103
- Congenital thrombophilia, cerebral infarction and, 58
- Constraint-induced movement therapy, for spasticity, 164
- Continuous hemofiltration, intracerebral hemorrhage and, 99
- Convalescent phase, of rehabilitation, 146, 153–154
- Coronary artery disease, prevention of, 20–22
- Corticosteroids  
 for antiphospholipid syndrome, 57  
 for aortitis syndrome, 140–141  
 for cerebral infarction prevention, 56–57  
 for cerebral infarction treatment, 40–41  
 for intracerebral hemorrhage, 80–81  
 for shoulder impairment, 166–167
- Cost-effectiveness analysis, of unruptured cerebral aneurysm treatment, 127
- Cough reflex test, 168–170
- Craniectomy, decompression, for cerebral infarction, 43–44
- Craniocervical junction, arteriovenous fistula in, 93
- Craniotomy  
 for arteriovenous malformations, 123–124  
 for cerebral aneurysms, 127  
 for intracerebral hemorrhage, 85–86, 99
- CSPS (Cilostazol Stroke Prevention Study), 60
- CT. *See* Computed tomography
- Cyanoacrylate glue, for arteriovenous malformations, 90
- Cycle ergometers, for decreased physical fitness, 175–177
- Dabigatran  
 for cerebral infarction prevention, 66  
 for stroke prevention, 23–24
- Danaparoid, for cerebral infarction, 36–37
- Dantrolene sodium, for spasticity, 163–166
- Davis neurodevelopmental exercise, 157
- Day-care rehabilitation, in chronic phase, 154–156
- DECIMAL study, of cerebral infarction, 43–44
- Decompression craniectomy, for cerebral infarction, 43–44
- Deep and subcortical white matter hyperintensity lesions, 119
- Deep brain stimulation, for central pain, 167–168
- Deep venous thrombosis  
 in cerebral infarction, 41–43  
 in intracerebral hemorrhage, 82  
 in patent foramen ovale, 136–138
- Defibrase, for cerebral infarction, 40, 56
- Defibrillation, for atrial fibrillation, 55
- Defibrinogenation therapy, for cerebral infarction, 40, 56
- Delayed vasospasm, in subarachnoid hemorrhage, 114–115
- Dementia, vascular, 142–143
- Depressive state  
 in cerebral aneurysms, 125  
 in cerebral infarction, 68  
 in intracerebral hemorrhage, 83–84  
 rehabilitation for, 173–175, 179–180  
 white matter lesions in, 119
- Desmoteplase, for cerebral infarction, 32
- DESTINY study, of cerebral infarction, 43–44
- Detrusor dysfunction, 170–171
- Dextran, for cerebral infarction, 40–43
- Diabetes mellitus  
 control of, for cerebral infarction prevention, 51–52  
 intracerebral hemorrhage and, 76  
 kidney disease with, 29–30  
 stroke and, 19–20

- Dialysis, intracerebral hemorrhage and, 98–99
- Diazepam, for spasticity, 163–166
- Diet, for intracerebral hemorrhage prevention, 75–77
- Digital subtraction angiography, for subarachnoid hemorrhage, 103
- Dipyridamole, for cerebral infarction, 48, 59–60
- Direct clipping, of cerebral aneurysms, 108–109
- Dissection
  - of aorta, cerebral infarction with, 45–46
  - arterial
    - headache in, 14
    - medical treatment of, 130–131
    - surgical treatment of, 131–133
  - of cerebral artery, 45
- Disturbances
  - attention, 173–175
  - intellectual, 173–175
  - urinary, 170–171
- Diuretics
  - for cerebral infarction prevention, 50–51
  - for cerebral venous/venous sinus occlusion, 138–139
  - for stroke prevention, 16–19
  - for subarachnoid hemorrhage, 103
- Dome/neck ratio, of aneurysms, 111
- Donepezil, for Alzheimer's disease, 142–143
- Doppler evaluation, for vasospasm, 114
- Drinking. *See* Alcohol consumption
- DSA (digital subtraction angiography), for subarachnoid hemorrhage, 103
- Dural arteriovenous fistula, intracerebral hemorrhage in, 92–93
- Duraplasty, for cerebral infarction, 43–44
- Dyslipidemia
  - cerebral infarction and, 52–53
  - kidney disease with, 29–30
  - stroke and, 20–22
- Dysphagia
  - aspiration pneumonia prevention in, 68–69
  - rehabilitation for, 168–170
  - in stroke, 13–14
- EAFT (European Atrial Fibrillation Trial), 63
- Early use of eXisting PREventive Strategies for Stroke study (EXPRESS), 47–50
- EAS (encephaloarteriosynangiosis), for moyamoya disease, 133–134
- Eating, dysphagia in, 168–170
- Ebselen, for cerebral infarction, 38–39
- ECASS III study, 8, 9, 34
- EC-IC (extracranial-intracranial) bypass, for cerebral infarction, 72–73
- ECST study, of cerebral infarction, 48
- Edaravone
  - for cerebral infarction, 37–39
  - for moyamoya disease, 134
- Edema, brain
  - in cerebral infarction, 39–40
  - in intracerebral hemorrhage, 80–81
  - in stroke, 11
- EDO Trial for antiplatelet therapy, 37
- EDS (encephalodurosynangiosis), for moyamoya disease, 133–134
- Education, family and patient
  - for rehabilitation, 156
  - for urinary disturbances, 170–171
- Efonidipine, for stroke prevention, 17
- Eicosapentaenoic acid, for cerebral infarction prevention, 52–53
- Elbow, impairment of, rehabilitation for, 161–163
- Electrical stimulation
  - deep brain, 167–168
  - for depressive state, 179–180
  - functional, 157, 159, 166–167
  - transcranial, 179–180
  - transcutaneous, 163–166
  - for upper arm impairment, 161–163
- Electro-acupuncture, for spasticity, 164
- Electrotherapy stimulation, for upper arm impairment, 161–163
- Embolism, artery-to-artery, 61
- Embolization
  - for arteriovenous malformations, 89–90, 123–124
  - for cerebral aneurysms, 110–113, 127
  - for dural arteriovenous fistulas, 92–93
  - of parent artery, 111
- Emotional behavior disorders, rehabilitation for, 173–175
- EMS (encephalomyosynangiosis), for moyamoya disease, 133–134
- Encephaloarteriosynangiosis, for moyamoya disease, 133–134
- Encephalodurosynangiosis, for moyamoya disease, 133–134
- Encephalomyosynangiosis, for moyamoya disease, 133–134
- Encephalopathy, hypertensive, 141
- Endarterectomy, carotid. *See* Carotid endarterectomy
- Endovascular treatment
  - for aortitis syndrome, 141
  - for arterial dissection, 131–133
  - for cerebral aneurysms, 110–113
  - for dural arteriovenous fistula, 92–93
- Enteral feeding, in dysphagia, 68–69, 168–170
- EPA (eicosapentaenoic acid), for cerebral infarction prevention, 52–53
- Eprosartan, for cerebral infarction prevention, 51
- Equinovarus foot, gait training for, 159–161
- Ergometers, for decreased physical fitness, 175–177
- Escitalopram, for depression, 68
- ESPRIT (European/Australasian Stroke Prevention in Reversible Ischaemia Trial), 47–50, 61
- État criblée (dilated perivascular spaces), detection of, 117–118
- Ethanol nerve block, for spasticity, 163–166
- Etidronic acid, for osteoporosis, 177–178
- European Atrial Fibrillation Trial (EAFT), 63
- European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT), 47–50, 61
- Evaluation methods, for rehabilitation, 147–149
- Executive impairment, rehabilitation for, 173–175
- Exercise(s)
  - for cognitive impairment, 173–175
  - for decreased physical fitness, 175–177
  - for depressive state, 179–180
  - for dysphagia, 168–170
  - for gait disorder, 159–161
  - for intracerebral hemorrhage, 82
  - for osteoporosis, 177–178
  - in rehabilitation, 151
  - for shoulder impairment, 166–167
  - for spasticity, 163–166
  - for transient ischemic attack, 46–50
  - for upper arm impairment, 161–163
  - for urinary disturbances, 171
- EXPRESS (Early use of eXisting PREventive Strategies for Stroke) study, 47–50
- Extracorporeal circulation, for cerebral infarction, 40
- Extracranial-intracranial bypass
  - for cerebral artery stenosis, 121–122
  - for cerebral infarction, 72–73
- Facilitation techniques, 157

- Factor VIIa, for intracerebral hemorrhage, 77–78
- Falls, prevention of, in osteoporosis, 177–178
- Family education, for rehabilitation, 156
- Famotidine, for intracerebral hemorrhage, 81
- Fasudil, for vasospasm, 114–115
- FES. *See* Functional electrical stimulation
- Fever
  - in intracerebral hemorrhage, 82
  - in stroke, 12–13
- Fibrinogen-lowering therapy, for cerebral infarction, 40, 56
- Fibrinolytic therapy, for subarachnoid hemorrhage, 112
- Fibromuscular dysplasia, 140
- Fibular nerve stimulation, for gait training, 159
- FIM (Functional Independence Measure), 147–148
- Fitness, decreased, rehabilitation for, 175–177
- Flexible endoscopic evaluation of swallowing with sensory testing, 168–170
- Flexor hallucis longus transfer, for gait training, 159
- Fluoxetine
  - for depressive state, 68, 179–180
  - for motor impairment rehabilitation, 157
- Folic acid
  - for cerebral infarction prevention, 57
  - for osteoporosis, 177–178
- FOOD trial report, on dysphagia, 169
- Foot, equinovarus, gait training for, 159–161
- Foramen ovale, patent, thrombosis due to, 136–138
- Force-use therapy, for shoulder impairment, 166
- 4S (Scandinavian Simvastatin Survival Study), 20–22
- Fraxiparine, for cerebral infarction, 36–37
- Fresh frozen plasma
  - for anticoagulant excess, 96–98
  - for intracerebral hemorrhage, 77–78
- Fugl-Meyer assessment scale, for rehabilitation, 147–148
- Functional electrical stimulation, 157
  - for gait training, 159
  - for shoulder impairment, 166–167
- Functional Independence Measure, 147–148
- Gait training, 155, 159–161
  - for decreased physical fitness, 175–177
  - for spasticity, 164
- Galantamine, for vascular dementia and cognitive impairment, 142–143
- Gastrointestinal bleeding
  - in intracerebral hemorrhage, 81
  - in rehabilitation, 151
  - in stroke, 12
- Gastrostomy tube, for dysphagia, 68–69, 168–170
- Gavestinel, for cerebral infarction, 38–39
- Glasgow Coma Scale, 42, 46
- Glioblastomas, 96
- Glucose control
  - in cerebral infarction prevention, 51–52
  - in stroke prevention, 19–20
- Glucose tolerance, physical fitness rehabilitation for, 175–177
- Glue, for arteriovenous malformations, 90
- Glutamic acid receptor antagonists, for cerebral infarction, 38–39
- Glycerol
  - hypertonic
    - for cerebral infarction, 39–40
    - for intracerebral hemorrhage, 80–81
    - for stroke, 11
  - for moyamoya disease, 134
- GOS (Glasgow Coma Scale), 42, 46
- Group therapy, for speech disorders, 171–172
- Guidelines. *See* Japanese Guidelines
- Guidelines for the Management of Hypertension, 7–8
- HAMLET study, of cerebral infarction, 43–44
- HAS-BLED risk score, 66
- Headache, in stroke, 14
- Heart failure, in CHADS score, 23
- Heart Protection Study, 19, 20
- Heart rate coefficient, in decreased physical fitness, 175–177
- Heat therapy, for spasticity, 163–166
- Hematocrit, reduction of, for cerebral infarction prevention, 56
- Hematomas
  - in amyloid angiopathy, 139–140
  - cisternal, vasospasm due to, 114–115
- Hemiparesis, rehabilitation for
  - in chronic phase, 155
  - with decreased physical fitness, 175–177
  - with motor impairment, 156–158
  - with osteoporosis, 177–178
  - with shoulder impairment, 166–167
  - with spasticity, 163–166
  - upper limb, 161–163
- Hemispatial neglect, rehabilitation for, 173–175
- Hemodialysis, intracerebral hemorrhage and, 98–99
- Hemodilution
  - for cerebral infarction, 40
  - for vasospasm, 114
- Hemorrhage. *See also* Bleeding
  - intracerebral. *See* Intracerebral hemorrhage
  - in moyamoya disease, 135–136
  - subarachnoid. *See* Subarachnoid hemorrhage
- Hemostatic agents, for intracerebral hemorrhage, 77–78
- Heparin
  - for anticoagulant excess, 96–98
  - for arterial dissection, 130–131
  - for cerebral infarction prevention, 63
  - for cerebral infarction treatment, 36–37, 41–43
  - for cerebral venous/venous sinus occlusion, 138–139
  - for intracerebral hemorrhage, 82
  - low-molecular-weight, for cerebral infarction, 36–37
- Heparinoid, for cerebral infarction, 36–37
- Herniation, cerebral, 9
- Hess and Hunt scale, for subarachnoid hemorrhage, 100–101
- Histamine-2 receptor antagonists, for gastrointestinal bleeding, 12
- HMG-CoA reductase inhibitors. *See* Statins
- Home-based rehabilitation, 15, 154–156
- Homocysteine excess, cerebral infarction and, 57
- HOT Study, 19–20
- HPS (Heart Protection Study), 19, 20
- Hunt and Kosnik classification, of subarachnoid hemorrhage, 100
- Hydralazine, contraindicated, for intracerebral hemorrhage, 79
- Hydrocephalus
  - in cerebellar infarction, 43–44
  - in subarachnoid hemorrhage, 113
- Hydroxyethyl starch, for cerebral infarction, 40
- Hydroxyvitamin D<sub>3</sub>, for osteoporosis, 177–178
- Hyperbaric oxygen therapy
  - for cerebral infarction, 41
  - for intracerebral hemorrhage, 80
- Hypercholesterolemia
  - cerebral infarction and, 52–53
  - kidney disease with, 29–30
  - stroke and, 20–22, 52–53
- Hyperdynamic therapy, for vasospasm, 114–115
- Hyperglycemia
  - correction of, 10–11
  - in rehabilitation, 151
- Hyperhomocysteinemia, cerebral infarction and, 57

- Hypertension (intracranial), in intracerebral hemorrhage, 80–81
- Hypertension (systemic)
- artificial, for vasospasm, 114
  - control of. *See also* Antihypertensive(s)
  - for intracerebral hemorrhage prevention, 75–77
  - for subarachnoid hemorrhage, 103
  - for vascular dementia and cognitive impairment, 142–143
  - intracerebral hemorrhage in, 77–82
  - non–salt-sensitive, 7
  - prevention of, 82–83
  - in stroke, 16–19
  - subarachnoid hemorrhage risk in, 101–102
  - white matter lesions in, 119
- Hypertension in the Very Elderly Trial (HYVET), 18
- Hypertensive encephalopathy, 141
- Hyperthermia, in rehabilitation, 151
- Hypertonic glycerol
- for cerebral infarction, 39–40
  - for intracerebral hemorrhage, 80–81
  - for stroke, 11
- Hyperventilation, for intracerebral hemorrhage, 80
- Hypocholesterolemia, intracerebral hemorrhage and, 75–76
- Hypoglycemia, correction of, 10–11
- Hyponatremia
- prevention of, in cerebral aneurysm repair, 109
  - in subarachnoid hemorrhage, 113
- Hypotension, drug-induced, for cerebral aneurysm repair, 109
- Hypothermia
- for cerebral infarction, 41
  - for intracerebral hemorrhage, 81–82
  - therapeutic, 12–13
- HYVET (Hypertension in the Very Elderly Trial), 18
- Ibuprofen, for cerebral infarction prevention, 61, 67–68
  - Ifenprodil, for cerebral infarction prevention, 61, 67–68
  - Immunosuppressive agents, for amyloid angiopathy, 139
  - Incontinence, urinary, rehabilitation for, 170–171
- Indapamide
- for cerebral infarction, 48
  - for vascular dementia and cognitive impairment, 142
- Infarction, cerebral, 31–73
- acute, 32–45
  - anticoagulants after, 63–67
  - anticoagulants during, 36–37
  - antidepressants after, 68
  - antiphospholipid syndrome and, 56–57
  - antiplatelet therapy after, 58–63
  - antiplatelet therapy during, 37–38
  - aortic dissection with, 45–46
  - artery-to-artery embolism, 61
  - aspiration pneumonia prevention after, 68–69
  - asymptomatic, 117–118
  - atherothrombotic, 31
  - atrial fibrillation control after, 55
  - brain edema in, 39–40
  - carotid artery revascularization for, 44–45
  - carotid artery stenting after, 70–72
  - carotid endarterectomy after, 69–70
  - carotid endarterectomy during, 44
  - in cerebral arterial dissection, 45
  - cerebral circulation and metabolism enhancers for, 67–68
  - in cerebral venous/venous sinus occlusion, 46
  - chronic, 50–73
  - classification of, 31
  - corticosteroids for, 40–41
  - decompressive craniectomy for, 43–44
  - diabetes mellitus control after, 51–52
  - dyslipidemia control after, 52–53
  - extracranial-intracranial bypass for, 72–73
  - fibrinogen-lowering therapy after, 56
  - fibrinogen-lowering therapy during, 40
  - headache in, 14
  - hematocrit lowering after, 56
  - hemodilution therapy for, 40
  - hyperbaric oxygen therapy for, 41
  - hyperhomocysteinemia control after, 57
  - hypertension control after, 50–51
  - hypothermic treatment for, 41
  - incidence of, 31
  - lifestyle changes after, 53–54
  - metabolic syndrome and, 54–55
  - neuroprotective agents for, 38–39
  - noncarotid artery stenting after, 72
  - obesity and, 54–55
  - outcomes of, 31
  - prevention of, 32, 46–67
  - rehabilitation for, 153
  - silent, 116–120
  - thrombolytic therapy for, 32–36
  - thrombophilia and, 58
  - thrombosis prevention in, 41–43
  - transient ischemic attack before, 46–50
- Infections
- in stroke, 11–13
  - subarachnoid hemorrhage risk in, 102
- Insulin resistance, stroke and, 28–29
- Intellectual disturbance, rehabilitation for, 173–175
- INTERACT (Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage) trial, 78
- Intermittent pneumatic compression, for cerebral infarction, 41–43
- International Medical Information Center, in guideline development, 3
- International Stroke Trial (IST), for anticoagulants, 36–37
- International Study of Unruptured Intracranial Aneurysms, 126–127
- International Surgical Trial in Intracerebral Haemorrhage, 74, 85
- Intracerebral hemorrhage, 74–99
- anticoagulant-induced, 96–98
  - in arteriovenous malformation, 88–92
  - asymptomatic, 120–121
  - in brain tumor, 96
  - in cavernous angioma, 94–95
  - chronic, management of, 82–84
  - in dural arteriovenous fistula, 92–93
  - hypertensive
    - brain edema in, 80–81
    - gastrointestinal bleeding management in, 81
    - hypothermia for, 81–82
    - nonsurgical treatment of, 77–82
    - respiratory management in, 80
    - seizure control in, 81
    - surgical treatment of, 84–88
    - thrombosis prevention in, 82
  - incidence of, 74
  - mortality in, 74
  - prevention of, 75–77
  - rehabilitation for, 153
  - in renal failure, 98–99
  - surgical treatment of, 74
  - in venous angioma, 95–96
- Intracranial cerebral artery stenosis, 121–122
- Intracranial hemorrhage, in thrombolytic therapy, 33–34
- Intracranial hypertension, in intracerebral hemorrhage, 80–81

- Intraventricular hemorrhage, 85–88
- Ipriflavone, for osteoporosis, 177–178
- Irbesartan, for atrial fibrillation, 23
- Ischemia
- in arterial dissection, 130–133
  - after cerebral aneurysm treatment, 112
  - in moyamoya disease, 133–136
- IST (International Stroke Trial), for anticoagulants, 36–37
- J-ACT (Japan Alteplase Clinical Trial), 32, 34–35
- JAM (Japanese Adult Moyamoya Trial), 136
- Japan Alteplase Clinical Trial (J-ACT), 32, 34–35
- Japan Atherosclerosis Society
- in guideline development, 5
  - guidelines for prevention of atherosclerosis, 21
- Japan Atrial Fibrillation and Stroke Trial (JAST), 23
- Japan Coma Scale, 152–153
- Japan EPA Lipid Intervention Study (JELIS), 52–53
- Japan Lipid Intervention Trial (J-LIT), 21
- Japan Multicenter Stroke Investigator's Collaboration Study (J-MUSIC), 23
- Japan Neurological Society, in guideline development, 1
- Japan Public Health Center-Based Prospective Study on Cancer and Cardiovascular Disease (JPHC Study), 25
- Japan Stroke Scale, 147–148
- Japan Stroke Society
- in guideline development, 1
  - "Guidelines for appropriate intravenous thrombolytic therapy using rt-PA," 32
  - Japan Stroke Scale, 147–148
- Japanese Adult Moyamoya Trial (JAM), 136
- Japanese Association of Rehabilitation Medicine
- evaluation methods of, 147–149
  - in guideline development, 1, 3
  - guidelines changes of, 145–146
- Japanese Circulation Society, in guideline development, 5
- Japanese Conference on Surgery for Cerebral Stroke
- classification, 74
- Japanese Diabetes Society, in guideline development, 5
- Japanese Guidelines for the Management of Stroke 2004
- development of, 1–6
  - on rehabilitation, 145–146
  - therapies available in, 31–32
- Japanese Guidelines for the Management of Stroke 2009
- development of, 1–6
  - organization structure of, 3–4
  - on rehabilitation, 145–146
- Japanese Investigation of Kinetic Evaluation in Hypertensive Events and Remodeling Treatment (JIKEI HEART) study, 17
- Japanese Rhythm Management Trial for Atrial Fibrillation (J-RHYTHM), 24
- Japanese Society for Detection of Asymptomatic Brain Diseases
- Brain Check-Up program of, 117
  - white matter lesion definition of, 119
- Japanese Society of Hypertension
- in guideline development, 5
  - Guidelines for the Management of Hypertension, 7–8, 17, 50–51
  - hypertension guidelines for, 19–20
- Japanese Society of Nephrology, in guideline development, 5
- Japanese Society of Neurological Therapeutics, in guideline development, 1
- Japanese Society of Thrombosis and Hemostasis, in guideline development, 5
- Japanese Stroke Data Bank, 7
- Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS), 7–8, 17
- JAST (Japan Atrial Fibrillation and Stroke Trial), 23
- JATOS (Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients), 7–8, 17
- JCS (Japan Coma Scale), 152–153
- J-curve phenomenon
- in alcohol consumption, 53–54
  - in hypertension, 50–51
- JELIS (Japan EPA Lipid Intervention Study), 52–53
- JET study, 72
- JIKEI HEART (Japanese Investigation of Kinetic Evaluation in Hypertensive Events and Remodeling Treatment) study, 17
- J-LIT (Japan Lipid Intervention Trial), 21
- J-MARS post-marketing alteplase study, 35
- J-MUSIC (Japan Multicenter Stroke Investigator's Collaboration Study), 23
- Joint angle biofeedback, for gait training, 159
- JPHC (Japan Public Health Center-Based Prospective Study on Cancer and Cardiovascular Disease) study, 25
- J-RHYTHM (Japanese Rhythm Management Trial for Atrial Fibrillation) study, 24
- JSS (Japan Stroke Scale), 147–148
- Kallidinogenase, contraindicated, for intracerebral hemorrhage, 79
- Keio Cooperative Stroke Study, 86
- Kidney dysfunction
- intracerebral hemorrhage and, 76, 98–99
  - stroke and, 29–30
- KLIS (Kyushu Lipid Intervention Study), 20
- KYOTO HEART study, 18
- Kyushu Lipid Intervention Study (KLIS), 20
- Lactate threshold, in decreased physical fitness, 175–177
- Lacunar infarction, 117–118
- antiplatelet therapy for, 58–63
  - incidence of, 31
  - rehabilitation for, 153
- Lamotrigine, for central pain, 167–168
- Language disorders, rehabilitation for, 171–172
- Lansoprazole, for intracerebral hemorrhage, 81
- Lateral putaminal hemorrhage, 84–88
- Leg ergometer, for decreased physical fitness, 175–177
- Leg massage, for intracerebral hemorrhage, 82
- Levodopa, for motor impairment rehabilitation, 157
- LIFE (Losartan Intervention for Endpoint Reduction in Hypertension Study), for stroke prevention, 17
- Lifestyle changes
- for cerebral infarction prevention, 53–54
  - for chronic kidney disease, 29–30
  - for intracerebral hemorrhage prevention, 75–77
  - for stroke prevention, 25–26
  - for TIA, 46–50
- LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease), 20
- Lisinopril, for stroke prevention, 16–17
- Lobal hemorrhage, 83–88
- Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID), 20
- Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE), for stroke prevention, 17
- Low-molecular-weight heparin, for cerebral infarction, 36–37, 41–43
- Lumboperitoneal shunt, for cerebral aneurysms, 113



- Magnesium, for cerebral infarction, 38–39
- Magnetic resonance angiography  
 for aortitis syndrome, 140–141  
 for dural arteriovenous fistula, 92–93  
 for subarachnoid hemorrhage, 103  
 for unruptured cerebral aneurysms, 124–125
- Magnetic resonance imaging  
 for asymptomatic cerebral infarction, 117  
 for venous angiomas, 95–96  
 for white matter lesions, 119
- Malnutrition  
 prognosis with, 11  
 in rehabilitation, 151
- Management of Atherothrombosis with Clopidogrel in High-risk patients with recent TIA or ischemic stroke (MATCH) trial, 47–50, 60
- Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) study, 20
- Mannitol  
 for cerebral infarction, 39–40  
 for intracerebral hemorrhage, 80–81  
 for stroke, 11
- MAS (Modified Ashworth Scale), for rehabilitation, 147–148
- MATCH (Management of Atherothrombosis with Clopidogrel in High-risk patients with recent TIA or ischemic stroke) trial, 47–50, 60
- Mathew scale, for rehabilitation, 147
- Mecobalamin, for osteoporosis, 177–178
- Medical Research Council/British Heart Foundation Heart Protection Study, 19
- MEGA (Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese) study, 20
- MELT-Japan Trial, 32
- Memantine, for vascular dementia and cognitive impairment, 142–143
- Memory impairment, rehabilitation for, 173–175
- Menatetrenone, for osteoporosis, 177–178
- Mendelsohn maneuver, for dysphagia, 168–170
- Metabolic syndrome  
 cerebral infarction and, 54–55  
 stroke and, 8, 27–28  
 white matter lesions in, 119
- Metastasis, to brain, intracerebral hemorrhage in, 96
- Methylphenidate, for motor impairment rehabilitation, 157
- Mexiletine, for central pain, 167–168
- Microbleeds  
 in amyloid angiopathy, 139–140  
 in intracerebral hemorrhage, 76, 120–121
- Milnacipran, for depressive state, 179–180
- Milrinone, for vasospasm, 115
- Mini-mental state examination, for rehabilitation, 147
- Modified Rankin scale (mRS), 127
- Monitoring unit, in stroke care, 15
- Monosialoganglioside GM1, for cerebral infarction, 38–39
- Morbidity and Mortality after Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention (MOSES) trial, 51
- Mortality  
 in anticoagulant therapy, 97  
 in arteriovenous malformations, 123  
 in intracerebral hemorrhage, 74  
 stroke care unit effects on, 15  
 in subarachnoid hemorrhage, 100
- MOSES (Morbidity and Mortality after Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention) trial, 51
- Motor impairment, rehabilitation for, 156–158
- Moyamoya disease  
 asymptomatic, 135  
 treatment of  
   hemorrhagic, 135–136  
   medical, 134–135  
   surgical, 133–134
- MRA. *See* Magnetic resonance angiography
- MRI. *See* Magnetic resonance imaging
- Multidisciplinary team, for rehabilitation, 150–152, 174
- Multiple burr hole surgery, for moyamoya disease, 133–134
- Muscle(s), strength training for, for decreased physical fitness, 175–177
- Muscle atrophy, 151  
 spastic, rehabilitation for, 163–166  
 strengthening exercises for, 154–155
- Myoelectric biofeedback, for gait training, 159
- Nafamostat, 99
- NASCET study, of cerebral infarction, 48
- National Institutes of Health Stroke Scale scores, 31, 148
- National Stroke Association, antihypertensive therapy guidelines of, 10
- Neck flexion exercise, for dysphagia, 168–170
- Neglect, hemispatial, rehabilitation for, 173–175
- Nerve block, for spasticity, 163–166
- Neurodevelopmental exercise, 157
- Neuroprotective agents, for cerebral infarction, 38–39
- Neurotomy, peripheral, for spasticity, 164
- Nicaraven, for cerebral infarction, 38–39
- Nicardipine, for intracerebral hemorrhage, 78–79
- Nicergoline  
 for cerebral infarction prevention, 61, 67–68  
 for vascular dementia and cognitive impairment, 142–143
- Nicotine replacement therapy, 25–26
- NIHSS (National Institutes of Health Stroke Scale), 148
- Nilvadipine  
 for asymptomatic cerebral infarction, 118  
 contraindicated for intracerebral hemorrhage, 78
- Nimodipine  
 for cerebral infarction, 38–39  
 for stroke, 10  
 for vasospasm, 114
- Nitrates, for intracerebral hemorrhage, 78
- NMDA receptor inhibitors, for vascular dementia, 142–143
- Nonsteroidal antiinflammatory drugs  
 for shoulder impairment, 166–167  
 for vascular dementia and cognitive impairment, 142–143
- Nonvalvular atrial fibrillation  
 cerebral infarction in, 36–37  
 stroke in, 23–25
- Normothermia, with antipyretics, for cerebral infarction, 41
- Northern Manhattan Study, 119
- Nortriptyline, for depressive state, 68, 179–180
- Nottingham Health Profile and Motor Assessment Scale, for rehabilitation, 147
- NSA (National Stroke Association), antihypertensive therapy guidelines of, 10
- NSAIDs. *See* Nonsteroidal antiinflammatory drugs
- Number needed to treatment of, with aspirin, for cerebral infarction, 37–38
- Nutrition  
 dysphagia and, 168–170  
 for stroke, 10–11  
 supplementation of, 10–11
- NXY-059 radical scavenger, for cerebral infarction, 32, 38–39
- Obesity. *See also* Metabolic syndrome  
 cerebral infarction and, 54–55  
 increase in, 7

- stroke and, 28
- Occlusion
  - cerebral venous, 46, 138–139
  - of cerebral vessels, 121–123
  - of circle of Willis, 133–136
  - of parent artery, for cerebral aneurysms, 108–109
  - venous sinus, 46, 138–139
- Occupational rehabilitation, 154–156
- Occupational therapy, 154–155
- Omeprazole, for intracerebral hemorrhage, 81
- Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET), 17, 51
- Optokinetic stimulation, for hemispatial neglect, 173–175
- Orthosis, for spasticity, 163–166
- Osteoporosis, rehabilitation for, 177–178
- Outcomes, prediction of, 149–150
- Outpatient rehabilitation, in chronic phase, 154–155
- Oxygen consumption, in decreased physical fitness, 175–177
- Oxygen therapy
  - hyperbaric, for cerebral infarction, 41
  - for intracerebral hemorrhage, 80
  - for stroke, 9
- Ozagrel sodium
  - for cerebral infarction, 36–38
  - for moyamoya disease, 134
  - for vasospasm, 114–115
- Pain, central, rehabilitation for, 167–168
- Pain management, for subarachnoid hemorrhage, 103
- Papaverine, for vasospasm, 114–115
- Paradoxical thrombosis, 136–138
- Partial targeted embolization treatment, for arteriovenous malformations, 90
- Passive smoking, stroke and, 25–26
- PATE (Pravastatin Antiatherosclerosis Trial in the Elderly), 20
- Patent foramen ovale, thrombosis in, 136–138
- Patent Foramen Ovale in Cryptogenic Stroke Study, 137
- Patient education, for rehabilitation, 156
- Pediatric patients
  - arteriovenous malformations in, 90
  - cavernous angiomas in, 94–95
  - moyamoya disease in, 134
- Pelvic floor muscle exercise, for urinary disturbances, 171
- Pentastarch, for cerebral infarction, 40
- Percutaneous angioplasty
  - for cerebral infarction prevention, 72–73
  - for vasospasm, 114–115
- Percutaneous endoscopic gastrostomy tube, for dysphagia, 168–170
- Perindopril
  - for cerebral infarction, 48
  - for stroke prevention, 17
  - for vascular dementia and cognitive impairment, 142
- Perindopril Protection against Recurrent Stroke Study (PROGRESS), 48, 50–51, 75–76, 83
- Peripheral neurotomy, for spasticity, 164
- Peritoneal dialysis, intracerebral hemorrhage and, 98–99
- Perivascular spaces, dilated, detection of, 117–118
- Periventricular hyperintensity white matter lesions, 119
- Petrosal sinus, arteriovenous fistula in, 92–93
- Pharynx, stimulation of, for dysphagia, 168–170
- Phenol nerve block, for spasticity, 163–166
- Physical fitness, decreased, rehabilitation for, 175–177
- Physiotherapy, definition of, 154
- Pioglitazone, for cerebral infarction, 32, 51–52
- Piracetam, for cerebral infarction, 38–39
- Piroxicam, for shoulder impairment, 166
- Pituitary apoplexy, in brain tumor, 96
- Plasma expander, for cerebral infarction, 40
- Plasminogen abnormalities, in thrombophilia, 58
- Platelet transfusions, for intracerebral hemorrhage, 77–78
- Pneumonia
  - aspiration
    - in dysphagia, 13–14, 168–170
    - prevention of, 68–69
    - in rehabilitation, 151
- PNF (proprioceptive neuromuscular facilitation), 157
- Positioning, for intracerebral hemorrhage, 80–81
- Pravastatin Antiatherosclerosis Trial in the Elderly (PATE), 20
- Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER), 20
- Prednisolone
  - for aortitis syndrome, 141
  - for shoulder impairment, 166
- Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial, 47–50, 51, 60
- Prism glasses, for hemispatial neglect, 173–175
- PROactive (PROspective pioglitAzone Clinical Trial In macro Vascular Events) trial, 19, 52
- Procedural memory learning, 173–175
- PRoFESS (Prevention Regimen for Effectively Avoiding Second Strokes) trial, 47–50, 60
- Prognosis, prediction of, 149–150
- PROGRESS (Perindopril Protection against Recurrent Stroke Study), 48, 50–51, 75–76, 83
- Proprioceptive neuromuscular facilitation, 157
- PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive) trial, 19, 52
- PROSPER (Pravastatin in Elderly Individuals at Risk of Vascular Disease), 20
- Prostacyclin
  - for cerebral infarction, 37–38
  - for stroke, 10
- Protamine, for anticoagulant excess, 96–98
- Protein C abnormalities, in thrombophilia, 58
- Protein S abnormalities, in thrombophilia, 58
- Prothrombin complex
  - for anticoagulant excess, 96–98
  - for intracerebral hemorrhage, 77–78
- Prourokinase, for cerebral infarction, 35–36
- Proximal occlusion, of parent artery, for cerebral aneurysms, 108–109
- Pulmonary embolism
  - in cerebral infarction, 41–43
  - prevention of, in intracerebral hemorrhage, 82
- Putaminal hemorrhage, 84–88
- Quality of life, with unruptured cerebral aneurysms, 127
- Radical scavengers, for cerebral infarction, 32, 38–39
- Radiotherapy
  - for arteriovenous malformations, 123–124
  - for dural arteriovenous fistulas, 92–93
  - stereotactic
    - for arteriovenous malformations, 90, 123–124
    - for cavernous angiomas, 94–95
- Ramipril
  - for cerebral infarction prevention, 51
  - for stroke prevention, 17
- Randomised Evaluation of Long-term anticoagulation therapY (RE-LY) trial, 23–24, 66
- Range of motion exercises
  - for shoulder impairment, 166–167
  - for spasticity, 163–166
- Ranitidine

- for gastrointestinal bleeding, 12
- for intracerebral hemorrhage, 81
- Rankin scale, modified, 127
- REACH (REduction of Atherothrombosis for Continued Health) registry, 65
- Rebleeding
  - from cerebral aneurysms
  - prevention of. *See* Aneurysm(s), cerebral, treatment of statistics on, 113
  - in moyamoya disease, 135–136
- Reboxetine
  - for depression, 68
  - for motor impairment rehabilitation, 157
- Recombinant tissue plasminogen activator (rt-PA, alteplase), 8, 32
  - for cerebral infarction, 32–35
  - for cerebral venous/venous sinus occlusion, 138–139
  - contraindications to, 32–33
  - institutional standards for, 33–34
  - monitoring of, 33
  - treatment regimen for, 33
- Recovery exercises, for cognitive impairment, 173–175
- REduction of Atherothrombosis for Continued Health (REACH) registry, 65
- Rehabilitation, 145–180
  - for activities of daily living, 156–158
  - in acute phase, 146, 150–153
  - for central pain, 167–168
  - in chronic phase, 146, 154–156
  - for cognitive impairment, 173–175
  - complications developing in, 150–152
  - in convalescent phase, 146, 153–154
  - for decreased physical fitness, 175–177
  - for depressive state, 179–180
  - for dysphagia, 168–170
  - for each subtype, 152–153
  - evaluation for, 147–149
  - flow of, 146
  - for gait disorder, 159–161
  - goals for, 154
  - guideline changes in 2009, 145–146
  - home-based, 15, 154–156
  - for motor impairment, 156–158
  - occupational, 154–156
  - for osteoporosis, 177–178
  - patient/family education in, 156
  - phases of, 146
  - policy changes for, 145–146
  - predicting prognosis in, 149–150
  - for shoulder paralysis, 166–167
  - for spasticity, 163–166
  - special stroke unit for, 8, 14–16, 150–152
  - for speech disorder, 171–172
  - for upper limb impairment, 161–163
  - for urinary disturbances, 170–171
- RE-LY (Randomised Evaluation of Long-term anticoagulation therapy) trial, 23–24, 66
- Renal disorders
  - intracerebral hemorrhage and, 76, 98–99
  - stroke and, 29–30
- Repetitive saliva swallowing test, 168–170
- Repetitive transcranial magnetic stimulation, for central pain, 168
- Respiratory infections, after cerebral infarction, 68–69
- Respiratory management
  - for intracerebral hemorrhage, 80
  - for stroke, 9
- Rest, for subarachnoid hemorrhage, 103
- Retention, urinary, rehabilitation for, 170–171
- Revascularization
  - for aortitis syndrome, 140–141
  - for cerebral infarction, 44–45
  - for moyamoya disease, 133–134, 136
- Rhizotomy, selective, for spasticity, 164
- Risedronic acid, for osteoporosis, 177–178
- Rivaroxaban, for stroke prevention, 25
- Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin D Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF), 25
- Rivastigmine, for vascular dementia and cognitive impairment, 142–143
- ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin D Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation), 25
- ROM exercises
  - for shoulder impairment, 166–167
  - for spasticity, 163–166
- Rood method, 157
- Rotterdam Scan Study
  - for asymptomatic cerebral infarction, 117
  - for white matter lesions, 119
- rt-PA. *See* Recombinant tissue plasminogen activator (rt-PA, alteplase)
- SAPPHIRE trial, 71
- Sarpogrelate, for cerebral infarction prevention, 61
- Scandinavian Simvastatin Survival Study (4S), 20–22
- Scandinavian Stroke Scale, 15
- Scavengers, radical, for cerebral infarction, 32, 38–39
- Scottish Intracranial Vascular Malformation Study, 92
- SCU (stroke care units), 8, 14–16
- Sedation, for subarachnoid hemorrhage, 103
- Seizures
  - in arteriovenous malformations, 90
  - in intracerebral hemorrhage, 81, 83, 90
  - in rehabilitation, 151
  - in stroke, 13
  - in subarachnoid hemorrhage, 103
- Selective serotonin reuptake inhibitors, for depressive state, 179–180
- Selective thrombin inhibitors, for cerebral infarction, 36–37
- Selfotel, for cerebral infarction, 38–39
- Serotonin norepinephrine reuptake inhibitors, for depressive state, 179–180
- Shaker (neck flexion) exercise, 169
- Shoulder, impairment of, rehabilitation for, 161–163, 166–167
- Shoulder-hand syndrome, 166
- SICHPA (Stereotactic Treatment of ICH by Means of a Plasminogen Activator), 85
- Sigmoid sinus, arteriovenous fistula in, 92–93
- Silent brain infarction, 116–120
- Simvastatin, in stroke prevention, 19
- SIMVS (Scottish Intracranial Vascular Malformation Study), 92
- Single arm ergometry, for decreased physical fitness, 175–177
- Sleep apnea syndrome, stroke and, 26–27
- Sling, for shoulder impairment, 166–167
- Smoking
  - cessation of
    - for cerebral infarction prevention, 53–54
    - for stroke prevention, 25–26
    - for transient ischemic attack, 46–50
    - subarachnoid hemorrhage risk due to, 101–102
- Snoring, stroke and, 26–27
- Societas Neurologica Japonica, in guideline development, 1, 3

- Sodium, control of, in cerebral aneurysm repair, 109
- SPAF III (Stroke Prevention in Atrial Fibrillation III) trial, 65
- SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels), 52–53, 76
- Spastic talipes equinus, 159
- Spasticity, rehabilitation for, 163–166
- Speech disorders, rehabilitation for, 171–172
- Speltzer and Martin classification, for arteriovenous malformations, 89
- SPINAF (Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation) trial, 64–65
- STA-MCA (superior temporal artery/middle cerebral artery) anastomosis, for moyamoya disease, 133–134
- Standard Language Test of Aphasia, 171–172
- Statins
- for cerebral infarction prevention, 52–53
  - for cerebral infarction treatment, 37–38, 48
  - intracerebral hemorrhage and, 76
  - for stroke prevention, 20–22
  - for transient ischemic attack, 46–50
  - for vascular dementia and cognitive impairment, 143
  - for vasospasm, 114
- Stents
- for arterial dissection, 132
  - carotid artery, for cerebral infarction, 44, 70–72
- Stereotactic radiotherapy
- for arteriovenous malformations, 90, 123–124
  - for cavernous angiomas, 94–95
  - for dural arteriovenous fistula, 93
- Stereotactic Treatment of ICH by Means of a Plasminogen Activator (SICHPA), 85
- Steroids. *See* Corticosteroids
- Streptokinase, for cerebral infarction, 34
- Stress ulcers, in intracerebral hemorrhage, 81
- Stroke. *See also specific types*
- atherothrombotic, 31
  - cardioembolic, 31
  - incidence of, 7, 31
  - risk factors for, 7
  - types of, 7
- Stroke care units, 8, 14–16
- Stroke Impairment Assessment Set, for rehabilitation, 147–148
- Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL), 52–53, 76
- Stroke Prevention in Atrial Fibrillation III (SPAF III) trial, 65
- Stroke Treatment with Ancrod Trial, 40
- Stroke units, 8, 14–16
- Subarachnoid hemorrhage, 100–115
- classification of, 100–101
  - Hunt and Hess scale for, 100–101
  - incidence of, 100
  - mortality rate in, 100
  - prevention of, 101–102
  - prognosis for, 100
  - risk factors for, 101–102
  - severity of, 100–101, 106
  - temporal aspects of, 102
  - treatment of
    - conservative, 113–115
    - endovascular, 110–113
    - follow-up in, 112
    - initial, 102–105
    - perioperative management in, 109–110
    - procedures for, 108–109
    - selection of methods for, 106–107
    - timing of, 107–108
- Subcortical hemorrhage, 83, 84–88
- Sucralfate, for gastrointestinal bleeding, 12
- Sulfinpyrazone, for cerebral infarction prevention, 60
- Sunbathing, for osteoporosis, 177–178
- Support services, for rehabilitation, 156
- Supraglottic swallow, for dysphagia, 168–170
- Surgical treatment. *See also specific procedures*
- for antithrombotic-drug excess, 96–98
  - for arterial dissection, 131–133
  - for arteriovenous malformations, 89–90
  - for brain tumors, 96
  - for cavernous angiomas, 94–95
  - for cerebral infarction, 43–44
  - for dialysis-induced hemorrhage, 98–99
  - for dural arteriovenous fistulas, 92–93
  - for gait training, 159
  - for intracerebral hemorrhage, 84–88
  - for moyamoya disease, 133–134
  - for pituitary apoplexy, 96
  - for ruptured cerebral aneurysms, 107–110
  - for venous angiomas, 95–96
- SUs (stroke units), 8, 14–16
- Swallowing disorders
- aspiration pneumonia prevention in, 68–69
  - rehabilitation for, 168–170
  - in stroke, 13–14
- Swallowing provocation test, 168–170
- Systemic lupus erythematosus, cerebral infarction and, 56–57
- Syst-Eur study of dementia, 142
- Takayasu arteritis, 140–141
- Tako-Tsubo cardiomyopathy, in subarachnoid hemorrhage, 103
- Task-oriented training, for decreased physical fitness, 175–177
- Telmisartan
- for cerebral infarction prevention, 51
  - for cerebral infarction treatment, 48
  - for stroke prevention, 17
- Temporal artery/middle cerebral artery anastomosis, for moyamoya disease, 133–134
- TENS (transcranial electric stimulation), for depressive state, 179–180
- Thalamic hemorrhage, 84–88
- Thermotherapy
- for dysphagia, 168–170
  - for spasticity, 164
- Thrombolytic therapy. *See also specific drugs*
- for cerebral infarction
    - intraarterial, 35–36
    - intravenous, 32–35
  - for cerebral venous/venous sinus occlusion, 138–139
  - intracerebral hemorrhage due to, 96–98
  - for stroke, 10
  - transarterial, 35–36
- Thrombophilia, cerebral infarction and, 58
- Thrombosis
- in cerebral infarction, 41–43
  - paradoxical, 136–138
  - prevention of, in intracerebral hemorrhage, 82
- TIA. *See* Transient ischemic attack (TIA)
- Tibial nerve block, for gait training, 159–161
- Ticlopidine
- for cerebral infarction prevention, 5
  - intracerebral hemorrhage due to, 96–98
  - for transient ischemic attack
- Timed Walk assessments, for rehabilitation, 147
- Tirilazad, for cerebral infarction, 38–39
- Tizanidine, for spasticity, 163–166
- TNT (Treating to New Targets) trial, 21, 29

- TOAST clinical study, of anticoagulants, 36–37
- Todralazine, contraindicated, for intracerebral hemorrhage, 79
- Tolperisone, for spasticity, 163–166
- Transarterial thrombolytic therapy, for cerebral infarction, 35–36
- Transcranial electric stimulation, for depressive state, 179–180
- Transcranial ultrasonography, for cerebral aneurysms, 103–104
- Transcutaneous electrical nerve stimulation, for spasticity, 163–166
- Transient ischemic attack (TIA), 46–50
- antiplatelet therapy for, 37–38
  - atrial fibrillation and, 55
- Trapping
- for arterial dissection, 132
  - of parent artery, for cerebral aneurysms, 108–109
- Trazodone, for depressive state, 68, 179–180
- Treadmill training, 159–160, 175–177
- Treating to New Targets (TNT) trial, 21, 29
- Triamcinolone acetonide, for shoulder impairment, 166–167
- Triceps surae, cooling of, for spasticity, 164
- Tricyclic antidepressants
- after cerebral infarction, 68
  - for depressive state, 179–180
  - for urinary disturbances, 170–171
- Triple-H therapy, for vasospasm, 114–115
- Truncal artery stenosis, 61
- Trunk bending exercises, for decreased physical fitness, 175–177
- Trunk rotation, for hemispatial neglect, 173–175
- Tumors, brain, intracerebral hemorrhage with, 96
- UKPDS 34 trial, 19–20
- Ulcers, gastric, in intracerebral hemorrhage, 81
- Ultrasonography, transcranial, for cerebral aneurysms, 103–104
- Underwater exercise, for decreased physical fitness, 175–177
- Unruptured cerebral aneurysms, 124–128
- Unruptured cerebral arteriovenous malformations, 46
- Upper limb impairment, rehabilitation for, 161–163
- Urinary disturbances, rehabilitation for, 170–171
- Urinary tract infections, in rehabilitation, 151
- Urokinase
- for cerebral infarction, 32–35
  - for cerebral venous/venous sinus occlusion, 138–139
  - for intracerebral hemorrhage, 86
- US Cerebral Embolism Task Force, anticoagulant guidelines of, 36–37
- Valsartan, for stroke prevention, 17, 18
- Vascular cognitive impairment, rehabilitation for, 173–175
- Vascular dementia, 142–143
- Vascular stenosis/occlusion, asymptomatic, 121–123
- Vasospasm, in subarachnoid hemorrhage, 110, 113–115
- Venous angiomas, 95–96
- Venous sinus occlusion, 46, 138–139
- Ventilation, for intracerebral hemorrhage, 80
- Ventilatory threshold, in decreased physical fitness, 175–177
- Ventricular drainage, for cerebral infarction, 43–44
- Ventriculoperitoneal shunt, for cerebral aneurysms, 113
- Vertebral artery, dissection of, 132
- Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation (VA-SPINAF) trial, 64–65
- Vibratory stimulation, for hemispatial neglect, 173–175
- Videofluoroscopic swallow examination, for dysphagia, 13–14, 68–69, 168–170
- Visceral obesity
- cerebral infarction and, 54–55
  - stroke and, 28–29
- Visual search training, for hemispatial neglect, 173–175
- Vitamin D, for osteoporosis, 177–178
- Vitamin K
- for moyamoya disease, 135
  - for warfarin excess, 96–98
- Waist-to-hip circumference ratio, cerebral infarction and, 54–55
- Walking. *See also* Gait training
- for decreased physical fitness, 175–177
- Wallenberg syndrome, 169
- Warfarin
- for arterial dissection, 130–131
  - for atrial fibrillation, 23–25
  - for cerebral infarction prevention, 51, 55–58, 63–67
  - for cerebral venous/venous sinus occlusion, 138–139
  - intracerebral hemorrhage due to, 96–98
  - for transient ischemic attack, 46–50
- WASID trial, 51
- Water swallowing test, for dysphagia, 13–14, 168–170
- Western Aphasia Battery, 171–172
- White matter lesions, asymptomatic, 118–120
- World Federation of Neurosurgical Societies, subarachnoid hemorrhage classification of, 100
- Wrapping, of cerebral aneurysms, 108–109
- Wrist, impairment of, rehabilitation for, 161–163
- Ximelagatran, for cerebral infarction, 32
- Yi-gan san, for vascular dementia and cognitive impairment, 143
- Zoledronic acid, for osteoporosis, 177–178
- Zonisamide, for central pain, 167–168